Patient engagement in oncology

The European Medicines Agency (EMA) is working closely with partners in the European medicines regulatory network and at international level to improve engagement with people living with and affected by cancer. Europe accounts for a quarter of all cancer cases recorded worldwide.

For more information on cancer medicines, see:

• Cancer medicines

Conversations on Cancer

EMA is collaborating with the United States (US) Food and Drug Administration (FDA) to organise public panel discussions with cancer patients and patient representatives.

This meeting series is titled 'Conversations on Cancer'. 

It invites inclusive and diverse panel members to examine cancer-related social issues such as oncology nursing and lung cancer in non-smokers.

EMA joined FDA in organising these public discussions in 2023. 

FDA started holding this series in 2020.

To access related event pages and get more information on meeting formats, participants and objectives, select the expandable panel below (via the arrow symbol):

Conversations on Cancer: event pages

• Conversations on cancer - cervical cancer treatment innovation: a collaborative discussion (14/01/2025)
• Conversations on Cancer - Pediatric Cancers: Navigating the Challenges Together (19/11/2024)
• Conversations on Cancer: Transforming Patient Lives by Therapeutic and Regulatory Innovations (01/02/2024)
• Conversations on Cancer presents “Living with Metastatic Breast Cancer” (19/10/2023)